Extraspinal ependymoma at the cervicothoracic junction

Yu, Y. L.; Crockard, H. A.; Smith, J. J.; Harries, Bethan

doi:10.1016/0090-3019(82)90266-x

Cited by 15 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These tumors occurs usually in the distal aspect of the spinal cord, in the conus-cauda-filum terminale region, but can also be observed in the cervical or thoracic spinal cord or extradurally (5). Infrequently, MPE can be observed in the lateral ventricle (6) or brain parenchyma (7).…”

Section: Introductionmentioning

confidence: 98%

The Results of Surgery, With or Without Radiotherapy, for Primary Spinal Myxopapillary Ependymoma: A Retrospective Study From the Rare Cancer Network

Pica

Miller

Villà

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

107

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

The Results of Surgery, With or Without Radiotherapy, for Primary Spinal Myxopapillary Ependymoma: A Retrospective Study From the Rare Cancer Network

Pica

Miller

Villà

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

107

View full text Add to dashboard Cite

“…Vaigawala [28] used an aggressive combination of chemotherapeutic agents in a relapsing patient. Yu et al [36] administered methotrexate and doxorubicin to a relapsing patient with pleural metastases, achieving unsatisfactory results, and Morantz [13] used polychemotherapy for two relapsing pediatric patients, reporting no evidence of relief. On the other hand, Rao [37] used neoadjuvant chemotherapy consisting of 3 cycles of cisplatin/etoposide and bleomycin in a 16-month-old female with a large pelvic mass, achieving a more than 50% reduction in the size of the lesion, plus another three adjuvant courses, achieving a CR.…”

Section: Managementmentioning

confidence: 99%

Pediatric extraspinal sacrococcygeal ependymoma (ESE): an Italian AIEOP experience of six cases and literature review

et al. 2018

View full text Add to dashboard Cite

Pediatric patients with this peculiar disease need to be referred to specialized pediatric cancer centers that can provide multidisciplinary treatment after a centralized pathology review. Our experience highlights the role of chemotherapy and radiotherapy in adjuvant and relapse setting. The final prognosis is relatively optimistic, but with a careful follow-up due to the high risk of recurrence.

show abstract

“…Spinal myxopapillary ependymoma (MPE) is a rare tumor primarily affecting children and young adults with a median age at diagnosis of 35 years old 1–3 . MPE typically arises from the conus medullaris, cauda equina, and filum terminale region, although MPE arising from other sites in the neuroaxis have been described 4–7 . MPE is considered a benign tumor, but a more aggressive course with multifocal involvement or dissemination can occur, especially in pediatric cases 8–13 .…”

Section: Introductionmentioning

confidence: 99%

“…equina, and filum terminale region, although MPE arising from other sites in the neuroaxis have been described. [4][5][6][7] MPE is considered a benign tumor, but a more aggressive course with multifocal involvement or dissemination can occur, especially in pediatric cases. [8][9][10][11][12][13] Distant disease can involve any area of the neuroaxis; intracranial metastases are rare but have been reported.…”

mentioning

confidence: 99%

Outcomes following limited‐volume proton therapy for multifocal spinal myxopapillary ependymoma

Looi

Indelicato

Vega

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Purpose Spinal myxopapillary ependymoma (MPE) often presents with a multifocal distribution, complicating attempts at resection. There remains no standard approach to irradiating these patients. We report disease control and toxicity in pediatric patients with multifocal spinal MPE treated with limited‐volume proton therapy. Materials/methods Twelve patients (≤21 years old) with multifocal spinal MPE were treated between 2009 and 2018 with limited‐volume brain‐sparing proton therapy. Median age was 13.5 years (range, 7‐21). Radiotherapy was given as adjuvant therapy after primary surgery in five patients (42%) and for recurrence in seven (58%). No patient received prior radiation. Eleven patients (92%) had evidence of gross disease at radiotherapy. Eleven patients received 54 GyRBE; one received 50.4 GyRBE. Treatment toxicity was graded per the CTCAEv4.0. We estimated disease control and survival using the Kaplan‐Meier product‐limit method. Results The median follow‐up was 3.6 years (range, 1.8‐10.6). The five‐year actuarial rates of local control, progression‐free survival, and overall survival were 100%, 92%, and 100%, respectively. One patient experienced an out‐of‐field recurrence in the spine superior to the irradiated region. No patients developed in‐field recurrences. Following surgery and irradiation, one patient developed grade three spinal kyphosis and one patient developed grade 2 unilateral L5 neuropathy. Conclusion 54 GyRBE to a limited volume appears effective for disseminated spinal MPE in both the primary and salvage settings, sparing children the toxicity of full craniospinal irradiation. Compared with historical reports, this approach using proton therapy improves the therapeutic ratio, resulting in minimal side effects and high rates of disease control.

show abstract

Extraspinal ependymoma at the cervicothoracic junction

Cited by 15 publications

References 5 publications

The Results of Surgery, With or Without Radiotherapy, for Primary Spinal Myxopapillary Ependymoma: A Retrospective Study From the Rare Cancer Network

The Results of Surgery, With or Without Radiotherapy, for Primary Spinal Myxopapillary Ependymoma: A Retrospective Study From the Rare Cancer Network

Pediatric extraspinal sacrococcygeal ependymoma (ESE): an Italian AIEOP experience of six cases and literature review

Outcomes following limited‐volume proton therapy for multifocal spinal myxopapillary ependymoma

Contact Info

Product

Resources

About